Antibodies in Lung Cancer Research
Jack (Jie) Huang MD, PhD
Chief Scientist I Founder/CEO I Visiting Professor I Medical Science Writer I Inventor I STEM Educator
Antibodies in lung cancer research can help researchers identify and study key biomarkers, understand tumor biology, and develop targeted therapies. Because they can specifically bind to proteins or antigens, they have become a valuable tool for diagnosing and treating various lung cancer subtypes, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
In lung cancer diagnosis, antibodies are primarily used to detect specific lung cancer biomarkers, such as epidermal growth factor receptor (EGFR), ALK (anaplastic lymphoma kinase), and PD-L1 (programmed death ligand 1). These markers are important in determining the molecular characteristics of lung cancer, thereby guiding treatment decisions. For example, EGFR mutations can guide the use of targeted therapies such as gefitinib or erlotinib, while PD-L1 expression helps assess eligibility for immunotherapy with checkpoint inhibitors such as pembrolizumab.
In immunohistochemistry (IHC) and immunofluorescence (IF) staining, antibodies help visualize the presence and distribution of these biomarkers in lung cancer tissue. This provides insights into tumor heterogeneity, immune evasion mechanisms, and interactions within the tumor microenvironment, which are critical to understanding how lung cancer progresses and responds to treatment.
Antibodies also play a central role in applications for lung cancer research, including western blots, flow cytometry, and enzyme-linked immunosorbent assays (ELISAs), which help researchers detect and quantify cancer-associated proteins.
In addition, the development of antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic drugs, offers a promising new avenue for targeting lung cancer cells while minimizing damage to healthy tissue.
Overall, antibodies are integral to lung cancer research, and they can drive diagnostic innovations and the development of more personalized, effective lung cancer therapies.
领英推荐
?
References
[1] Astri Frafjord et al., Scandinavian Journal of Immunology 2020 (https://doi.org/10.1111/sji.12889 )
[2] Deepali Jain et al., Cancer Cytopathol 2019 (doi:?10.1002/cncy.22137)
[3] Shang-Gin Wu et al., PLoS One 2011 (doi:10.1371/journal.pone.0023303)
Experimental Medicine , Faculty of Medicine, UBC, Vancouver | Medical Content Writing
1 个月What methodology was used to determine the impact of antibodies on lung cancer research, and what are the implications? https://lnkd.in/gsaeuFhu
Developer Full-Stack | AI-Powered Solutions Enthusiast | Expert in Hospitality Management & Web Development | Passionate about UX Design & Innovative Marketing Strategies | Based in Phnom Penh.
1 个月Jack Huang MD, PhD I’m exploring the potential of AI-driven models like TxGNN for advanced stage 4 cancer treatment, especially in cases with metastases in multiple areas (e.g., lung, spine, rib). The model shows promise in drug repurposing and personalized therapy, with potential treatment improvements of 5% to 20%. Before moving forward, I’m seeking input from specialists: How practical is it to apply models like TxGNN in complex, real-world cases? Are the potential improvements significant enough to consider this approach for optimizing current treatments? Any expert insights would be greatly valued bests regard Nicolas delrieu
...
1 个月Many Congratulations sir